Core Insights - The global drug development outsourcing market is projected to grow from $151.2 billion in 2023 to $363.2 billion by 2030, with a CAGR of 13.3% [1] - AI is becoming a key driver in new drug discovery, enabling rapid screening and optimization of potential candidates, which may shorten drug discovery timelines [1][4] - By 2026, leading companies in the AI+pharmaceutical sector, such as Crystal and TEMPUS, are expected to achieve positive EBITDA for the first time, indicating a valuation restructuring phase for the industry [1][3] Market Overview - The North American market has significant private data barriers in the medical field, which is essential for effective AI applications [1] - The complexity of medical processes and reliance on expert judgment highlight the need for advanced AI solutions in drug development [1] - The potential market space for drug development outsourcing is substantial, with a forecasted growth rate of 13.3% [1] Capital Developments - In 2026, leading AI+pharmaceutical companies are anticipated to see a dual impact on performance and valuation [3] - Crystal Holdings signed a collaboration agreement worth HKD 47 billion ($5.99 billion) with DoveTree, setting a record for AI pharmaceutical orders [3] - Crystal's drug discovery solutions generated revenue of RMB 435 million in H1 2025, reflecting a year-over-year increase of 616% [3] Technological Advancements - AI models, particularly deep learning and generative models, can efficiently learn complex relationships between molecular structures and biological activities [4] - AI's ability to predict key parameters such as binding affinity and toxicity can significantly enhance the success rate and efficiency of new drug discovery [4] National Support - Crystal has secured two major national science and technology projects, focusing on AI for Science and new materials [5] - The projects aim to build a scientific knowledge graph and an AI experimental platform to empower drug and material research [5] Investment Opportunities - Companies to watch in the AI+pharmaceutical sector include Crystal Holdings (02228), Insilico Medicine (03696), TempusAI (TEM.US), WuXi AppTec (02359), and HengRui Medicine (01276) [6]

Core Viewpoint - The company is set to engage in daily related transactions with its affiliates for the year 2025, which are deemed necessary for normal business operations and will not harm the interests of the company or its shareholders [9][10]. Summary by Sections Related Party Transactions - The company has disclosed its related party transactions, including expected amounts and categories, with specific affiliates such as Beijing Bai'ao Pharmaceutical Co., Ltd. and Jiangsu Yong'an Pharmaceutical Co., Ltd. [1][3][4][5][6]. - The expected transaction amounts are calculated based on the company's projected expenditures or revenues for similar business activities in 2024 [1]. Performance and Compliance - The affiliates involved in the transactions have good credit and financial conditions, ensuring their ability to fulfill contractual obligations without creating bad debts for the company [2]. - The company will sign contracts with related parties for the expected daily transactions in 2025, ensuring legal protection for performance [2][8]. Pricing Policy - The pricing policy for related party transactions is based on fair and just principles, using market prices as a reference. Agreements are made voluntarily and equitably [7]. Purpose and Impact - The anticipated related transactions are essential for the company's operational needs, aimed at consolidating market presence, enhancing operational capabilities, and promoting profit growth. The transactions are structured to avoid dependency on related parties [9][10]. Approval Process - The expected related party transactions for 2025 have been approved by the company's board and will be submitted for shareholder approval [10][21]. Financial Indicators - The company reported a significant increase in R&D investment, amounting to 171.94 million yuan in 2024, representing a 39.02% increase from 2023, with R&D expenses accounting for 15.94% of total revenue [46]. Competitive Advantages - The company has established a comprehensive drug development service model, enhancing its ability to meet diverse client needs and improve the success rate of drug development [38][39]. - The company has developed specialized core technology clusters in high-difficulty research areas, providing a competitive edge in the market [39][40]. Client Relationships - The company has built strong client relationships through integrated drug development services, serving approximately 1,000 pharmaceutical enterprises, which enhances customer loyalty and supports future business growth [45]. Regulatory Compliance - The company has adhered to relevant laws and regulations regarding fundraising and the use of raised funds, ensuring compliance and protecting shareholder interests [49]. Management Changes - The company has undergone changes in its board of directors, including the resignation of an independent director and the nomination of a new candidate, ensuring compliance with governance requirements [51][52].